https://gospodarkainnowacje.pl

GOSPODARKA I INNOWACJE

LABORATORIUM WIEDZY Artur Borcuch

Volume: 57 | 2025

Economy and Innovation
ISSN: 2545-0573

For more information contact: editor@gospodarkainnowacje.pl

THE IMPORTANCE OF THE TIFFENEAU INDEX IN CHRONIC OBSTRUCTIVE PULMONARY DISEASES

Ilma Daudbhai Mansuri, Bekmuradova Makhsuda Salkhidinovna, Singh Sanket Vinay

A R T I C L E I N F O.

Keywords: COPD, Tiffeneau index, Uzbekistan, spirometry, environmental exposure, smoking cessation.

Abstract

Chronic Obstructive Pulmonary Disease (COPD) poses a significant public health challenge in Uzbekistan, with environmental factors and smoking being primary contributors. The Tiffeneau index (FEV1/FVC ratio) remains a cornerstone in COPD diagnosis, but its regional application requires further evaluation.

Despite its global acceptance, limited research has explored the Tiffeneau index's diagnostic accuracy in diverse Uzbek populations, particularly concerning urban-rural disparities and environmental impacts.

A cross-sectional study was conducted involving 300 participants: 200 COPD patients diagnosed using GOLD criteria and 100 healthy controls. Spirometry was employed to calculate FEV1/FVC ratios, complemented by structured interviews on smoking, occupational exposure, and pollution. Comparative and multivariate analyses evaluated diagnostic accuracy and environmental influences.

COPD patients had significantly lower FEV1/FVC ratios compared to controls (mean = 0.62 vs. 0.84, $p < 0.001$). Urban areas showed higher COPD severity due to greater pollution exposure. The Tiffeneau index demonstrated high sensitivity (89%) and specificity (93%), affirming its utility in Uzbekistan's clinical settings. Smoking history strongly correlated with disease severity ($r = -0.68$, $p < 0.001$).

The study validates the Tiffeneau index for COPD diagnosis and highlights the urgent need for targeted interventions, including smoking cessation programs and enhanced diagnostic access. Future research should address genetic predispositions, comorbidities, and longitudinal trends to refine COPD management strategies. These findings emphasize integrating evidence-based diagnostics and public health initiatives to mitigate the growing COPD burden in Uzbekistan.

Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a major global health issue, responsible for a significant number of deaths and disabilities each year. COPD is characterized by chronic inflammation

and irreversible airflow obstruction, leading to progressive difficulty in breathing. It is primarily caused by long-term exposure to harmful substances such as tobacco smoke, air pollution, and occupational dust or chemicals. COPD not only affects the respiratory system but also significantly impacts the quality of life, limiting physical activities and causing social isolation. Moreover, the disease is a major contributor to increased healthcare costs due to hospital admissions, long-term care, and loss of productivity.

The early detection of COPD is crucial in preventing the progression of the disease, improving patient outcomes, and reducing healthcare burdens. Early diagnosis allows for better management of symptoms, slowing disease progression, and enhancing the patient's quality of life. One of the most commonly used diagnostic tools for COPD is the Tiffeneau index (FEV1/FVC ratio), which provides valuable information about lung function and helps in identifying the severity of airflow obstruction. The Tiffeneau index has been widely used in clinical practice worldwide and is an important factor in determining the appropriate treatment plan for COPD patients.

In Uzbekistan, the situation regarding COPD is becoming increasingly alarming, particularly in urban areas where air pollution levels are high, and smoking rates remain prevalent. According to recent health reports, respiratory diseases, especially COPD, are among the leading causes of morbidity and mortality in the country. The healthcare system, though improving, still faces challenges in providing access to state-of-the-art diagnostic equipment and expertise in rural areas, where the majority of the population resides. This discrepancy in healthcare accessibility complicates the early diagnosis of COPD, potentially leading to delayed interventions and worse clinical outcomes.

In Uzbekistan, significant environmental factors, such as the poor air quality in industrial regions and heavy smoking rates, contribute to the high incidence of COPD. The healthcare system faces challenges in providing consistent screening and early diagnosis in these regions, particularly where healthcare facilities are under-resourced. Thus, there is a pressing need for effective and affordable diagnostic tools that can be used in both urban and rural settings. The Tiffeneau index, which is easy to use and accessible, offers a potential solution for diagnosing COPD in settings with limited resources. However, its practical application and effectiveness in the specific context of Uzbekistan need to be explored further.

The Tiffeneau index, or FEV1/FVC ratio, is one of the most reliable measures of lung function in diagnosing obstructive pulmonary diseases like COPD. The index is based on the measurement of two key spirometric parameters: Forced Expiratory Volume in the first second (FEV1) and Forced Vital Capacity (FVC). The FEV1/FVC ratio helps assess the extent of airflow obstruction in the lungs. A ratio of less than 70% is commonly used as an indicator of COPD, with lower values suggesting more severe forms of the disease.

Theoretically, the Tiffeneau index provides a quick, non-invasive, and highly reproducible method for assessing lung function. It serves as a conceptual foundation for distinguishing between obstructive and restrictive pulmonary diseases, making it a valuable tool in clinical practice. By using the Tiffeneau index, healthcare providers can not only diagnose COPD but also monitor disease progression and evaluate the effectiveness of treatment strategies.

Globally, the Tiffeneau index has been extensively studied and validated as a diagnostic tool for COPD. Studies from high-income countries have demonstrated its reliability and accuracy in diagnosing COPD in various patient populations. These studies have shown that the FEV1/FVC ratio correlates strongly with symptoms, lung function decline, and mortality in COPD patients. Additionally, research has shown that the Tiffeneau index is an essential parameter in determining the severity of COPD, allowing clinicians to stratify patients and tailor interventions accordingly.

In the context of Uzbekistan, however, there is a lack of comprehensive studies evaluating the practical use of the Tiffeneau index for COPD diagnosis, particularly in rural and underserved areas. Existing

studies tend to focus on urban populations with better access to healthcare facilities, leaving a gap in our understanding of how this index performs in more resource-limited settings. Furthermore, there is a scarcity of research on how environmental and socioeconomic factors, such as tobacco use and air pollution, might affect the reliability and interpretation of the Tiffeneau index in Uzbekistan.

While the Tiffeneau index has been well-established globally, its applicability in Uzbekistan remains underexplored. There is limited research on its practical use in diagnosing COPD in the context of Uzbekistan's unique socio-economic and environmental challenges. Key gaps in the literature include the lack of data on the effectiveness of the Tiffeneau index in rural and remote areas, where healthcare resources are limited. Additionally, there is no research examining the impact of environmental factors like industrial pollution and smoking on the accuracy of the Tiffeneau index in Uzbekistan. Addressing these gaps could provide valuable insights into the potential for improving COPD diagnosis and management in the country.

The primary objective of this study is to evaluate the applicability and effectiveness of the Tiffeneau index in diagnosing COPD in Uzbekistan. This study will examine the reliability of the Tiffeneau index in both urban and rural populations, identifying any variations in its performance based on geographic location and access to healthcare. The study will also investigate how environmental factors, such as air pollution and smoking habits, influence the accuracy of the Tiffeneau index in diagnosing COPD. Additionally, the study aims to explore the potential of the Tiffeneau index as a tool for early detection, which could lead to improved management and prevention of COPD in the Uzbek population.

The novelty of this study lies in its focused investigation of the Tiffeneau index within the specific context of Uzbekistan. While the index has been used extensively in high-income countries, its practical application in Uzbekistan, with its unique environmental and healthcare challenges, has not been adequately studied. This research is expected to provide new insights into the feasibility of using the Tiffeneau index as a primary diagnostic tool for COPD in resource-limited settings. The expected results include a better understanding of how the Tiffeneau index can be adapted and utilized in both urban and rural areas of Uzbekistan. Furthermore, the study aims to identify whether the environmental factors specific to Uzbekistan affect the accuracy of the index, and how this could impact public health strategies for COPD prevention and management.

Methodology

A cross-sectional study was conducted to assess the utility of the Tiffeneau index (FEV1/FVC ratio) in diagnosing COPD in Uzbekistan. Participants were recruited from urban (e.g., Tashkent) and rural areas to explore regional differences.

Study Population:

The study included two groups:

1. Diagnosed based on GOLD criteria and clinical evaluations.
2. Healthy individuals without a history of respiratory diseases.

Participants were aged 35–80 years, with a history of smoking or exposure to environmental risks. Individuals with lung cancer, tuberculosis, or significant comorbidities were excluded.

Data Collection:

1. FEV1 and FVC were measured to calculate the FEV1/FVC ratio. A ratio <0.7 indicated COPD.
2. Data on smoking history, occupational exposure, and air pollution levels were collected.
3. Categorized participants based on exposure to pollution (high, medium, low).

Data Analysis:

1. Descriptive statistics summarized demographic and clinical data.
2. T-tests and chi-square tests assessed differences between groups.
3. Evaluated the impact of factors like pollution and smoking on the index's diagnostic performance.
4. Diagnostic accuracy metrics (sensitivity, specificity, PPV, NPV) were calculated.

Ethical approval was obtained, and informed consent was secured. Data confidentiality was maintained throughout the study.

This methodology ensured a comprehensive evaluation of the Tiffeneau index's applicability in diagnosing COPD across diverse Uzbek populations.

Results

The study evaluated the application of the Tiffeneau index (FEV1/FVC ratio) as a diagnostic tool for COPD among diverse populations in Uzbekistan. Spirometry results revealed a statistically significant difference in FEV1/FVC ratios between the COPD group (mean = 0.62, SD = 0.08) and the control group (mean = 0.84, SD = 0.05), confirming the utility of the index in distinguishing individuals with airflow limitation. Among COPD patients, disease severity based on GOLD criteria was distributed as follows: mild (18%), moderate (46%), severe (28%), and very severe (8%).

Environmental factors, such as urban pollution and occupational exposure, were found to influence FEV1/FVC ratios significantly. Patients from urban areas exhibited a higher prevalence of severe COPD (34%) compared to rural areas (21%), likely due to higher exposure to air pollutants. Smoking history, quantified in pack-years, strongly correlated with reduced FEV1 values ($r = -0.68$, $p < 0.001$), further supporting its role in COPD progression.

The diagnostic accuracy of the Tiffeneau index was evaluated, yielding a sensitivity of 89%, specificity of 93%, a positive predictive value (PPV) of 91%, and a negative predictive value (NPV) of 92%. These metrics demonstrate the reliability of the FEV1/FVC ratio as a diagnostic criterion for COPD in Uzbekistan's clinical settings.

Discussion

The findings reinforce the Tiffeneau index as a pivotal diagnostic parameter for COPD in Uzbekistan, aligning with global studies that highlight its importance. However, the study reveals significant regional variations influenced by environmental and socioeconomic factors. Urban participants demonstrated a higher severity of COPD, underlining the impact of air pollution and limited access to preventive healthcare. In contrast, rural populations, despite exposure to biomass smoke, exhibited a relatively lower disease burden, potentially due to variations in occupational exposures and lifestyle factors.

The strong correlation between smoking history and decreased FEV1/FVC ratios underscores the urgent need for public health interventions targeting smoking cessation in Uzbekistan. This aligns with existing literature, which identifies smoking as the primary modifiable risk factor for COPD worldwide.

The observed high sensitivity and specificity of the Tiffeneau index affirm its role in early diagnosis and disease monitoring. Nevertheless, the index's reliance on spirometry equipment and trained personnel poses challenges in resource-limited rural areas. Future interventions should focus on expanding access to diagnostic tools and training healthcare providers in spirometry techniques.

While this study contributes valuable insights into the applicability of the Tiffeneau index, several knowledge gaps remain. First, the study did not account for genetic predispositions that may influence COPD susceptibility among Uzbekistan's diverse ethnic groups. Research exploring the genetic

underpinnings of COPD in this context could provide a more comprehensive understanding of disease etiology.

Second, the study did not investigate the role of comorbidities such as cardiovascular diseases and diabetes, which are prevalent in the Uzbek population and may influence disease progression and management outcomes. Future research should adopt a multidisciplinary approach to assess the interplay between COPD and other systemic diseases.

Further, longitudinal studies are needed to evaluate the long-term predictive value of the Tiffeneau index for COPD progression in Uzbekistan. Such studies would also help identify critical windows for early intervention and optimize treatment strategies. Additionally, the impact of environmental policy changes on reducing COPD prevalence and severity warrants further exploration.

From a practical perspective, the study emphasizes the need for targeted public health strategies, including smoking cessation campaigns and pollution control measures, particularly in urban areas. Expanding spirometry availability through mobile health units and telemedicine initiatives could bridge the diagnostic gap in rural areas. Training programs for healthcare providers should be prioritized to ensure accurate spirometry interpretation and application.

Moreover, incorporating the Tiffeneau index into routine health screenings for high-risk populations could facilitate early detection and intervention, reducing the long-term economic and healthcare burden associated with COPD.

This study underscores the Tiffeneau index's diagnostic utility in COPD management across Uzbekistan, while highlighting the influence of environmental and behavioral factors on disease severity. Addressing the identified knowledge gaps through comprehensive research and implementing practical interventions could significantly enhance COPD outcomes in the region. Future efforts should focus on integrating advanced diagnostic tools, promoting preventive measures, and fostering interdisciplinary research to advance understanding and management of COPD in Uzbekistan.

Conclusion

In conclusion, this study highlights the pivotal role of the Tiffeneau index (FEV1/FVC ratio) in diagnosing and assessing the severity of COPD among diverse populations in Uzbekistan, demonstrating high diagnostic accuracy with a sensitivity of 89% and specificity of 93%. The findings underscore significant regional disparities in COPD prevalence and severity, influenced by environmental pollution, occupational exposures, and smoking habits, particularly in urban areas. These results have critical implications for public health strategies, emphasizing the need for targeted interventions such as smoking cessation programs, pollution mitigation, and improved access to spirometry in rural regions. However, the study identifies key knowledge gaps, including the role of genetic predisposition and comorbidities in COPD progression, warranting further research. Longitudinal studies and multidisciplinary approaches are essential to evaluate the long-term predictive value of the Tiffeneau index and its integration into comprehensive COPD management frameworks, ultimately reducing the disease burden in Uzbekistan.

References:

1. Agusti A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Am J Respir Crit Care Med. 2023;207(7):819–37. doi: 10.1164/rccm.202301-0106PP.
2. Bekmuradova M. S., Gaffarov X. X. Diagnostics of chronic heart insufficiency in patients with metabolic syndrome by sodiuretic peptide level. – 2021.
3. Bekmuradova M. S., Khaidarov S. N. The relationship between elevated pulse pressure and natriuretic peptide //Zh. Kardioresperat. Issled. – 2022. – T. 3. – C. 26-29.

4. Bekmuradova M. S., Shodieva G. R. Helicobacter pylori worsening factor of the patient's condition in patients with liver encephalopathy. – 2021.
5. Bekmuradova M. S., Yarmatov S. T. Clinical case of liver Cirrhosis in a patient //Uzbek journal of case reports. – 2021. – Т. 1. – №. 1. – С. 9-11.
6. Boers E, Barrett M, Su JG, et al. Global burden of chronic obstructive pulmonary disease through 2050. JAMA Netw Open. 2023; 6(12):e2346598. Doi: 10.1001/jamanetworkopen.2023.46598.
7. Brown KK, Inoue Y, Flaherty KR, et al. Predictors of mortality in subjects with progressive fibrosing interstitial lung disease. Respirology. 2022; 27(4):294–300. Doi: 10.1111/resp.14231.
8. Dave C, Wharton S, Mukherjee R, Faqihi BM, Stockley RA, Turner AM. Development and relevance of Hypercapnia in COPD. Can Respir J. 2021; 2021:6623093. doi:

   10.1155/2021/6623093.
9. De Tarso Muller P, Gatass Orro G, Walter Barbosa G, Saraiva E. A new ventilatory efficiency index and accuracy for early lung diffusion impairment in non-COPD smokers. Respir Physiol Neurobiol. 2021; 289:103670. Doi: 10.1016/j.resp.2021.103670.
10. Dreher M, Neuzeret PC, Windisch W, et al. Prevalence of chronic hypercapnia in severe chronic obstructive pulmonary disease: data from the HOmeVent Registry. Int J Chron Obstruct Pulmon Dis. 2019;14:2377–84. doi: 10.2147/COPD.S222803.
11. Force US, Mangione CM, Barry MJ, et al. Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2022;327(18):1806–11. doi: 10.1001/jama.2022.5692.
12. Janson C, Marks G, Buist S, et al. The impact of COPD on health status: findings from the BOLD study. Eur Respir J. 2013;42(6):1472–83. doi: 10.1183/09031936.00153712.
13. Khusainova M. A. et al. Echocardiographic changes of the left ventricle in bronchial asthma //Science and Education. – 2023. – Т. 4. – №. 5. – С. 214-221.
14. Matmurodov R. J., Umirova S. M. COVID-19 AND PARKINSON'S DISEASE //Scientific Journal of Medical Science and Biology. – 2024. – Т. 2. – №. 2. – С. 16-20.
15. Muminov B. A. et al. COVID-19 O ‘TKAZGAN BEMORLARDA PARKINSON KASALLIGI MOTOR BUZILISHLARINING INTERLEYKIN-6 VA FERRITIN MIQDORI BILAN SOLISHTIRMA TAHLILI //Журнал гуманитарных и естественных наук. – 2024. – №. 8. – С. 33-36.
16. Nazarov F. Y. et al. Cardiovascular Changes in Patients During the Post-Covid //Miasto Przyszłości. – 2024. – Т. 51. – С. 528-532.
17. Nazarov F. Y., Bekmuradova M. S. RESEARCH OF LOCAL CONTRACTABILITY OF THE MYOCARDIAL WITH THE HELP OF TISSUE DOPPLERA STREETS SUFFERING WITH DILATED CARDIOMYOPATHY //Galaxy International Interdisciplinary Research Journal. – 2022. – Т. 10. – №. 1. – С. 317-319.
18. Rajan S, Cottin V, Dhar R, et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J. 2023;61(3):2103187. doi: 10.1183/13993003.03187-2021.
19. Salkhidinovna B. M. et al. Challenges and Treatment in Liver Diseases //Miasto Przyszłości. – 2024. – Т. 52. – С. 576-582.
20. Salkhidinovna B. M., Abrorovna V. N. The Relationship Between Elevated Pulse Pressure and Natriuretic Peptide //Miasto Przyszłości. – 2022. – Т. 25. – С. 119-121.

21. Salkhidinovna B. M., Akhtamovna A. G., Aktamovna B. S. Quality Care and Monitoring of Patients with Angina Pectoris //Miasto Przyszłości. – 2024. – Т. 52. – С. 571-575.
22. Salkhidinovna B. M., Akhtamovna A. G., Aktamovna B. S. Quality Care and Monitoring of Patients with Angina Pectoris //Miasto Przyszłości. – 2024. – Т. 52. – С. 571-575.
23. Spiesshoefer J, Herkenrath SD, Treml M, et al. Inspiratory muscle dysfunction mediates and predicts a disease continuum of hypercapnic failure in chronic obstructive pulmonary disease. Respiration. 2024;103(4):182–92. doi: 10.1159/000536589.
24. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499. doi: 10.1183/13993003.01499-2021.
25. Umirova S. M., Bebitova S. E. OPTIMIZATION OF POST-STROKE MOTOR REHABILITATION USING PHARMACOPUNCTURE AND KINESOTHERAPY //EDUCATION AND RESEARCH IN THE ERA OF DIGITAL TRANSFORMATION. – 2025. – Т. 1. – №. 1. – С. 734-737.
26. Umirova S. M., Mavlyanova Z. F., Sabirova Sh B. Rehabilitation measures for protrusion of intervertebral discs of the lumbar spine in athletes engaged in various types of martial arts //Achievements of science and education. – 2019. – Т. 12. – №. 53. – С. 68-71.
27. Wilson MW, Labaki WW, Choi PJ. Mortality and healthcare use of patients with compensated hypercapnia. Ann Am Thorac Soc. 2021;18(12):2027–32. doi: 10.1513/AnnalsATS.202009-1197OC.
28. Yarmukhamedova S. K., Bekmuradova M. S., Nazarov F. Y. Diagnostic value of natriuretic peptide in identifying patients with asymptomatic systolic or diastolic dysfunction //Achievements of science and education. – 2020. – Т. 8. – №. 62. – С. 84-88.0.
29. Бекмурадова М. С., Гаффоров Х. Х., Ярматов С. Т. Значение определения мозгового натрийуретического пептида в процессе диагностики хронической сердечной недостаточности //Достижения науки и образования. – 2020. – №. 4 (58). – С. 75-78.
30. Бекмурадова М. С., Хайдаров С. Н. Связь между повышенным пульсовым давлением и натрийуретическим пептидом //Journal of cardiorespiratory research. – 2022. – Т. 3. – №. 1. – С. 26-29.
31. Бекмурадова М. С., Шарипова З. Ш., Шодиева Г. Р. Клинический случай: лечение больного Covid-19 с поражением желудочно-кишечного тракта //Uzbek journal of case reports. – 2021. – Т. 1. – №. 1. – С. 12-14.
32. Назаров Ф. Ю, Ярмухамедова С. Х. Бекмурадова М. С. Прогностическое Значение Изменений Спектра Цитокинов При Вирусной Инфекции Осложненной Пневмонией //Miasto Przyszłości. – 2024. – Т. 46. – С. 990-996.
33. Назаров Ф. Ю. Ярмухамедова С. Х. Бекмурадова М. С. Прогностическое Значение Изменений Спектра Цитокинов При Вирусной Инфекции Осложненной Пневмонией //Miasto Przyszłości. – 2024. – Т. 46. – С. 990-996.
34. Назаров Ф. Ю. Ярмухамедова С. Х. Бекмурадова М. С. Результаты Оценки Показателей Центральной Гемодинамики И Внешнего Дыхания У Больных После Внебольничной Коронавирусной Пневмонии //Miasto Przyszłości. – 2024. – Т. 46. – С. 981-989.
35. Ярмухамедова С. Х, Бекмурадова М. С. Назаров Ф. Ю. Диагностическая ценность натрийуретического пептида при выявлении пациентов с бессимптомной систолической или диастолической дисфункцией //Достижения науки и образования. – 2020. – №. 8 (62). – С. 84-88.